

The Impact of Laboratory-based Prompts on the Management of Patients with Chronic Kidney Disease

Submission date
10/02/2006

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
10/07/2006

Overall study status
Completed

☐ Statistical analysis plan

☐ Results

Last Edited
14/02/2008

Condition category
Nutritional, Metabolic, Endocrine

☐ Individual participant data

☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Bruce Culleton

Contact details

1403-29th St NW

Calgary

Alberta

Canada

T2N 2T9

+1403 944 8166

bruce.culleton@calgaryhealthregion.ca

Additional identifiers

Study information

Scientific Title

Study objectives

A laboratory prompt, which identifies a patient with chronic kidney disease (CKD) as being at high risk for cardiovascular disease and progression to kidney failure, improves the management of cardiovascular disease risk factors and kidney disease by physicians.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by Bioethics Committess at the University of Calgary and the University of Alberta, 2005, reference number: 18050

Primary study design

Interventional

Study design

Cluster randomized trial

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Chronic kidney disease

Interventions

The following prompt will be added to laboratory reports for patients who meet the inclusion criteria and are seen by a physician practice randomized to receive the prompt:

This patient has reduced kidney function and is at risk for cardiovascular events and progression to kidney failure. The National Kidney Foundation recommends:

1. Measure random urine albumin to creatinine (Alb:Cr) ratio
2. Institute an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in patients with diabetes, or those with an Alb:Cr >35 mg/mmol
3. Referral to a nephrologist if GFR <30 ml/min/1.73 m²
4. Assess and treat modifiable risk factors for cardiovascular (CV) and renal disease:
 - a. Target blood pressure (BP) less than 130/80 mmHg
 - b. Target low-density lipoprotein cholesterol(LDL-C) <2.5 mmol/l
 - c. If diabetic, target hemoglobin A1C (HbA1C) <7.0%

The above recommendations are general in nature and may not apply to all patients. Further information is available at <http://www.akdn.info>

The control group will receive usual care.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Use of ACEi or ARB in patients >65 years of age with CKD who have a clear indication for ACEi or ARB use as defined by the presence of diabetes or significant albuminuria.

Key secondary outcome(s)

1. Use of an ACEi or ARB in patients >65 years of age with CKD
2. Subsequent measurement of lipids, hemoglobin A1C (in patients with diabetes, if not done in previous six months), urine protein or urine albumin, and subsequent frequency of measurement of serum creatinine
3. Referral to a specialist
4. Addition of cholesterol-lowering drugs in patients >65 years of age
5. Addition of new blood pressure medication(s) in patients >65 years of age
6. Health care costs

Completion date

31/03/2008

Eligibility**Key inclusion criteria**

All patients >18 years of age who are registered with one of the participating general practices and have a GFR measured at <60 ml/min during the one-year study period will be included. All participating general practices will be geographically separated (not located in the same office building), and staffed by >1 full time practitioners who do not see outpatients in another general practice unit (to reduce the risk of contamination).

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Those patients not meeting the inclusion criteria.

Date of first enrolment

01/04/2006

Date of final enrolment

31/03/2008

Locations**Countries of recruitment**

Canada

Study participating centre

1403-29th St NW

Alberta

Canada

T2N 2T9

Sponsor information

Organisation

Alberta Heritage Foundation for Medical Research (Canada)

ROR

<https://ror.org/006b2g567>

Funder(s)

Funder type

Research organisation

Funder Name

Alberta Heritage Foundation for Medical Research (Canada)

Alternative Name(s)

AHFMR

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration